Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $425,000 a Year

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/24/2019 | 11:23am EDT

By Maria Armental

Novartis AG's gene therapy to treat a rare muscle-wasting disease that typically kills babies before age 2 was approved for sale in the U.S.

Zolgensma, a one-time injection to treat spinal muscular atrophy type 1 in children younger than 2, is the first gene therapy for pediatric patients.

SMA, as the hereditary disease is known for its acronym, is the leading cause of infant deaths.

There are four primary types of SMA based on age when symptoms first appear and highest milestone achieved. Many children with SMA type 1, a severe form and most common type, don't survive past the age of 2.

Novartis (NVS) said the annualized cost of Zolgensma will be $425,000 a year for five years.

Write to Maria Armental at maria.armental@wsj.com

Corrections & Amplifications

This article was corrected at 1:24 p.m. ET because an earlier version misspelled Zolgensma in the headline.

Corrections & Amplifications

This item was corrected at 6:23 p.m. ET. An earlier version misstated Novartis as Novaratis in the last paragraph.

This article is part of a news chaine.
Article 1 / 3
<< Preceding Next >>
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
04:15aGSK to sell two vaccines in $1.1 billion deal to focus on newer treatments
RE
03:58aGlaxoSmithKline to Sell Two Former Novartis Vaccines for up to EUR955 Million
DJ
10/18Sanofi pulls Zantac from U.S. and Canada after carcinogen found
RE
10/17INCYTE : Novartis announces that Jakavi meets primary endpoint in Phase III stud..
AQ
10/17INCYTE : Announces that the REACH2 Pivotal Trial of Ruxolitinib Meets Primary En..
AQ
10/16NOVARTIS : announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase ..
PU
10/16INCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
RE
10/15NOVARTIS : Sandoz and Pear Therapeutics announce Pear will solely commercialize ..
AQ
10/14EUROPE : European stocks hit pause as trade doubts linger
RE
More news
Financials (USD)
Sales 2019 46 899 M
EBIT 2019 13 789 M
Net income 2019 9 789 M
Debt 2019 17 416 M
Yield 2019 3,41%
P/E ratio 2019 18,3x
P/E ratio 2020 20,0x
EV / Sales2019 4,61x
EV / Sales2020 4,30x
Capitalization 199 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,02  $
Last Close Price 86,80  $
Spread / Highest target 23,8%
Spread / Average Target 8,31%
Spread / Lowest Target -7,26%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS15.10%198 751
JOHNSON & JOHNSON-1.05%337 021
ROCHE HOLDING AG18.88%250 869
MERCK AND COMPANY10.82%216 813
PFIZER-16.47%201 662
NOVO NORDISK AS17.69%123 560